Promises
1 promise
Promise Tracker
1 delivered, 0 close, 0 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q1 FY26
Glenmark's Q1 FY26 consolidated revenue was INR 32,644 million, up 0.6% YoY, with India formulation growing 3.7% and North America up 8.9% QoQ to $91M.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q1 FY26 consolidated revenue was INR 32,644 million, up 0.6% YoY, with India formulation growing 3.7% and North America up 8.9% QoQ to $91M. Europe declined 4% YoY but management expects double-digit growth from Q2. The India business saw secondary sales growth of 15.1% (IQVIA), significantly ahead of reported growth due to tail-end brand discontinuations. Key launches include LIRAFIT (liraglutide biosimilar) with >50% market share, and oncology brands TEVIMBRA and BRUKINSA. The IGI-AbbVie deal for ISB-2001 is expected to close in September, improving net debt to cash positive. EBITDA margin guidance of 23%+ from Q3 FY26. Risk: Monroe facility FDA observations remain unresolved, delaying commercial manufacturing and injectable filings.
ग्लेनमार्क की पहली तिमाही में कुल कमाई 3,264 करोड़ रुपये रही, जो पिछले साल से 0.6% ज्यादा है। भारत में दवाओं की बिक्री 3.7% बढ़ी, और उत्तरी अमेरिका में 8.9% का उछाल आया। यूरोप में बिक्री 4% घटी, लेकिन कंपनी को अगली तिमाही से दो अंकों की बढ़त की उम्मीद है। भारत में असली बिक्री 15.1% बढ़ी, लेकिन कुछ पुराने ब्रांड बंद होने से रिपोर्ट की गई बढ़त कम दिखी। नए उत्पादों में LIRAFIT (डायबिटीज की दवा) ने 50% से ज्यादा बाजार हिस्सा पा लिया है। कंपनी का कर्ज घटकर नकदी में बदलने वाला है। अगली तिमाही से मुनाफा 23% से ज्यादा रहने का अनुमान है। खतरा: अमेरिकी फैक्ट्री में अभी भी कमियां हैं, जिससे नई दवाओं का उत्पादन टल रहा है।
Promises1 met · 0 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Monroe facility FDA observations unresolved
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India secondary sales growth (IQVIA)
15.1%
+6.6pp vs IPM growth of 8.5%
Glenmark's India secondary sales grew 15.1% in Q1 FY26, outperforming the IPM growth of 8.5%.
LIRAFIT market share
>50%
New launch
Glenmark's liraglutide biosimilar LIRAFIT achieved over 50% market share in the molecule.
ISB-2001 overall response rate (Phase I)
79%
N/A (clinical data)
IGI's ISB-2001 showed 79% overall response rate in heavily pretreated multiple myeloma patients.
Net debt
INR 1,500 crore
Sequential increase from Q4 FY25
Net debt increased to INR 1,500 crore due to inventory buildup and one-time payments.
What Changed vs Last Quarter
NEW
India business to grow 10-15% CAGR over 3-5 years
Management expects India business to grow at 10-15% CAGR over the next three to five years, driven by branded products and new launches.
NEW
Europe to return to double-digit growth from Q2 FY26
Management anticipates Europe region returning to double-digit growth from Q2 FY26 and expects double-digit growth for full year FY26.
NEW
Emerging markets double-digit growth in FY26 on constant currency
Management expects emerging markets to record double-digit growth in FY26 on a constant currency basis.
UPDATED
EBITDA margin of 23%+ from Q3 FY26
Management guided that EBITDA margin will stabilize close to 23%+ from Q3 FY26 onwards, including the impact of generic Flovent launch.
DROPPED
Revenue growth 10%-12% in FY26
Consolidated revenue from operations expected to grow 10%-12% year-over-year in FY2026.
DROPPED
Cash generation INR 300-400 crore in FY26
Free cash flow (post-interest and dividends) expected to be INR 300-400 crore in FY2026.
DROPPED
Generic Flovent 44 mcg approval by end of Q2 FY26
Expects approval for generic Flovent 44 mcg strength by end of Q2 FY2026, with launch thereafter.
NEW RISK
Monroe facility FDA observations unresolved
The Monroe facility has five FDA observations; management is awaiting FDA response and hopes to restart commercial manufacturing this year, but timeline is uncertain.
NEW RISK
Antitrust litigation in US
Glenmark USA is involved in multidistrict antitrust litigation; settled with direct purchaser class for $37.75M, but other classes remain, with no visibility on timeline.
NEW RISK
India reported growth vs secondary sales divergence
India reported growth of 3.7% lags secondary sales growth of 15.1% due to tail-end brand discontinuations; convergence expected only from Q3.
NEW RISK
Net debt increase and working capital buildup
Net debt increased to INR 1,500 crore due to inventory buildup for launches and one-time payments; management expects stabilization but no specific timeline.
RISK GONE
U.S. FDA compliance issues at Pithampur and Monroe plants
Pithampur plant under FDA discussion; Monroe plant awaiting inspection. Delays could impact U.S. launch timelines.
RISK GONE
Diabetes portfolio erosion in India
Remogliflozin and Teneligliptin, which contributed ~60% of diabetes sales, faced generic competition; new launches (Lirafit, Empagliflozin) yet to fully offset decline.
RISK GONE
Delayed U.S. launches and lack of meaningful approvals
North America revenue declined 5.4% due to back-ended launches; Flovent and nasal spray approvals may slip further.
RISK GONE
IGI licensing deal uncertainty
ISB 2001 licensing deal is critical to fund IGI's $70M annual burn; any delay could pressure margins.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q4 FY25
EBITDA margin guided to 19%-20% for FY2026, driven by Ryaltris, U.S. launches, and R&D efficiencies.
Mentioned in Q1 FY25, Q3 FY25
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
Mentioned in Q1 FY25, Q2 FY25
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
Fast read
Guidance and risk preview
Management guided that EBITDA margin will stabilize close to 23%+ from Q3 FY26 onwards, including the impact of generic Flovent launch.
The Monroe facility has five FDA observations; management is awaiting FDA response and hopes to restart commercial manufacturing this year, but tim...
View Risks →